ValiRx plc (GB:VAL) has released an update.
ValiRx Plc’s subsidiary Inaphaea BioLabs has signed an agreement with Spanish research firm Xenopat to evaluate and commercially use Inaphaea’s Patient Derived Cells in Xenograft models. The deal includes upfront fees, service royalties, and a co-marketing arrangement, potentially extending beyond the initial 12-month term. This partnership is expected to accelerate the commercialization of Inaphaea’s biobank assets and expand its market presence.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
